Lowest Price Guaranteed From USD 5,499
Published
March 2021
Pages
770
View Count
12024
.PNG) |
.PNG) |
.PNG) |
 |
.PNG) |
 |
 |
 |
 |
 |
.PNG) |
Cancer is one of the leading causes of death worldwide, accounting for an estimated 1.8 million mortalities in 2020, in the US alone. Moreover, according to the World Health Organization, the number of newly diagnosed cancer cases is anticipated to grow by 70%, worldwide, over the next 20 years. Till date, it has been established that conventional treatment options, which include chemotherapy, radiation therapy, and surgery, are limited when it comes to treating late-stage cancers. Immunotherapy, especially T cell-based products, has emerged as a viable and promising treatment option, having demonstrated the capability to selectively target and eliminate tumor cells. Over time, the approval and clinical success of several chimeric antigen receptor (CAR) transduced T-cell based immunotherapy candidates, have inspired numerous research groups across the world, to focus their efforts on this relatively novel class of anticancer therapies. In fact, CAR-T cell therapies are presently considered among the most promising therapeutics available to treat various types of hematological malignancies and solid tumors. In addition, T-cell based therapies featuring CAR constructs designed against pathogenic entities that are characteristic of a number of non-oncological indications, are also under investigation.
Currently, there are four approved CAR-T cell therapies, namely KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences) and BREYANZI® (Bristol Myers Squibb / Juno Therapeutics). Owing to advances in fundamental research on disease biology, a myriad of viable biological targets that can be drugged using CARs have been identified. Leveraging available data, industry stakeholders are actively strengthening their respective pipelines; there are more than 755 CAR-T cell-based product candidates that are presently being evaluated in clinical and preclinical trials. This upcoming class of biologics is also driven by the availability of several innovative technology platforms that enable genetic manipulation and cell therapy development, and lucrative capital investments from both public and private investors. With multiple therapeutic leads in the mid to late-stages of development (phase II and above), and soon anticipated to enter the market, we are led to believe that the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.
The “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (Non-Hodgkin’s Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Colorectal Cancer), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, hepatocellular carcinoma and colorectal cancer), [B] target antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.
Chapter 3 provides a general overview of CAR-T cell therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell based therapies and the challenges associated with such therapies.
Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
Chapter 5 features an assessment of the CAR-T cell therapies that are currently approved or in different stages of development. It features a detailed analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (acute lymphoblastic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, brain cancer, chronic lymphocytic leukemia, pancreatic cancer, liver cancer, lung cancer, stomach cancer, ovarian cancer, breast cancer, mesothelioma, colon cancer, Hodgkin lymphoma, sarcoma, bone cancer, melanoma, and others), key target antigen (CD19, BCMA, CD22, CD20, GD2, Meso, CD38, CD123, MUC1, CD30, HER2, GPC3, CD33, EGFR, EGFRvIII, PD-L1, PSMA and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.
Chapter 6 presents a collection of key insights derived from the study. It includes an insightful representation highlighting the most popular targets of CAR-T therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapies (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.
Chapter 7 presents an analysis of the clinical trials of CAR-T registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.
Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 9 includes an overview of the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the CAR-T cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.
Chapter 10 provides a list of technology platforms that are either available in the market or under designed for the development of CAR-T cell therapies and a detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of CAR-T cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
Chapter 11 features a analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.
Chapter 12 provides details on the investments and grants that have been awarded to players focused on the development of CAR-T cell therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
Chapter 13 provides insights on cell therapy manufacturing, highlighting the current challenges in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.
Chapter 14 highlights our views on the various factors that must be taken into consideration while deciding the prices of CAR-T cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.
Chapter 15 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides an informed market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, hepatocellular carcinoma and colorectal cancer), [B] target antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).
Chapter 16 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 17 includes brief company profiles of the leading players in the CAR-T cell therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to CAR-T cell therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
Chapter 18 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 19 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Miguel Forte (Chief Operating Officer, TxCell), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).
Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapy
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Popular Target Indications
5.2.5. Analysis by Popular Target Antigens
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Analysis by Dose Frequency
5.2.9. Analysis by Target Patient Segment
5.2.10. Analysis by Type of Therapy
5.2.11. Key Industry Players: Distribution by Number of Therapies in Pipeline
5.2.12. Key Non-Industry Players: Distribution by Number of Therapies in Pipeline
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies
6.2.2. Popular Targets Related to Solid Tumors
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies
6.3. CAR-T Cell Therapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.4. CAR-T Cell Therapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China
8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.1.1. History of Development
8.2.2. Current Status of Development
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.1.1. History of Development
8.3.2. Current Status of Development
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. TECARTUS® / Brexucabtagene Autoleucel (Kite Pharma)
8.4.1. Therapy Overview
8.4.2. Current Status of Development
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen, Price and Manufacturing
8.5. JCAR (Juno Therapeutics (a Bristol Myers Squibb Company))
8.5.1. Therapy Overview
8.5.1.1. CAR-T Design
8.5.2. Current Status of Development
8.5.3. Key Clinical Results
8.5.3.1. JCAR014
8.5.3.2. JCAR017
8.5.3.3. JCAR018
8.5.3.4. JCARH125
8.5.4. Dosage Regimen and Manufacturing
8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol-Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Current Status of Development
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Nanjing Legend Biotech / Janssen Biotech)
8.7.1. Therapy Overview
8.7.2. Current Status of Development
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.8.1. Therapy Overview
8.8.2. Current Status of Development
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing
8.9. Next Generation CAR-T Cell therapies (Autolus)
8.9.1. Therapy Overview
8.9.2. Current Status of Development
8.9.3. Key Clinical Trial Results
8.9.3.1. AUTO1
8.9.3.2. AUTO3
8.9.4. Dosage Regimen and Manufacturing
8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.10.1. Therapy Overview
8.10.2. Current Status of Development
8.10.3. Dosage Regimen and Manufacturing
9. KEY THERAPEUTIC AREAS FOR CAR-T CELL THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. CAR-T Cell Therapies and Affiliated Research Landscape
9.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.3. Pancreatic Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.4. Liver Cancer
9.3.4.1. Introduction and Epidemiology
9.3.4.1. Current Treatment Landscape
9.3.4.2. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.5. Breast Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.6. Ovarian Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.7. Bladder Cancer
9.3.7.1. Introduction and Epidemiology
9.3.7.2. Current Treatment Landscape
9.3.7.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.8. Kidney Cancer
9.3.8.1. Introduction and Epidemiology
9.3.8.2. Current Treatment Landscape
9.3.8.3. CAR-T Cell Therapies and Affiliated Research Landscape
10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Applications of Genome Editing Technologies
10.2.2. Emerging Technology Platforms for CAR-T Cell Therapy Development and Production
10.2.2.1. CRISPR / Cas9 System
10.2.2.1.1. Key Components and Function
10.2.2.1.2. Mechanism of Action
10.2.2.1.3. Targeting Efficiency and Challenges
10.2.2.1.4. Next-GEN CRISPR Technology
10.2.2.1.5. Technology Providers
10.2.2.1.5.1. Editas Medicine
10.2.2.1.5.2. Intellia Therapeutics
10.2.2.1.5.3. CRISPR Therapeutics
10.2.2.1.5.4. Beam Therapeutics
10.2.2.1.5.5. Gracell Biotechnologies
10.2.2.2. TALENs
10.2.2.2.1. Key Components and Function
10.2.2.2.2. Mechanism of Action
10.2.2.2.3. Advantages and Challenges
10.2.2.2.4. Technology Providers
10.2.2.2.4.1. Cellectis
10.2.2.2.4.2. Editas Medicine
10.2.2.3. megaTAL
10.2.2.3.1. Technology Providers
10.2.2.3.1.1. bluebird bio
10.2.2.4. Zinc Finger Nuclease
10.2.2.4.1. Technology Providers
10.2.2.4.1.1. Sangamo Therapeutics
10.2.3. Competitive Analysis: Gene Editing Platforms
10.3. Designing CAR-T Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. Antibody Coupled T-Cell Receptor
10.3.1.1.1. Unum Therapeutics
10.3.1.2. NKR-T Platform
10.3.1.2.1. Celyad Oncology
10.3.1.2.2. Glycostem
10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt Technology
10.3.2.1.1. Juno Therapeutics
10.3.2.2. RheoSwitch Therapeutic System
10.3.2.2.1. Intrexon
10.3.2.3. Inducible Caspase 9 Safety Switch
10.3.2.3.1. Bellicum Pharmaceuticals
10.3.2.3.1.1. CaspaCIDe Technology
10.3.2.3.1.2. CIDeCAR Technology
10.3.2.3.1.3. GoCAR-T Technology
10.3.2.3. On-Off Switch, Multiple Companies
10.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.3.2. On-Off Switch (Theravectys)
10.3.2.4. Other Technologies to Improve CAR-T Safety
10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapy Market: List of Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Most Popular Products
11.3.4. Most Active Industry Players: Analysis by Number of Partnerships
11.3.5. Most Active Non-Industry Players: Analysis by Number of Partnerships
11.3.6. Most Active Contract Manufacturers: Analysis by Number of Manufacturing
11.3.7. Regional Analysis
11.3.8. Intercontinental and Intracontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapy Market: Funding and Investment Analysis
12.3.1. Analysis by Year of Investment
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Most Active Players: Analysis by Number of Funding Instances
12.3.5. Analysis by Type of Investor
12.3.6. Most Active Investors: Analysis by Number of Funding Instances
12.3.7. Regional Analysis by Amount Invested
13. CASE STUDY: CELL THERAPY MANUFACTURING
13.1. Chapter Overview
13.2. Overview of Cell Therapy Manufacturing
13.3. Cell Therapy Manufacturing Models
13.3.1. Centralized Manufacturing Model
13.3.2. Decentralized Manufacturing Model
13.4. Scalability of Cell Therapy Manufacturing Processes
13.4.1. Scale-Up
13.4.2. Scale-Out
13.5. Types of Cell Therapy Manufacturers
13.6. Key Challenges Associated with Manufacturing of Cell Therapies
13.7. Important Factors for Cell Therapy Manufacturing
13.7.1. Characterization
13.7.2. Cost of Goods
13.8. Automation of Cell Therapy Manufacturing Process
13.9. Cell Therapy Manufacturing Supply Chain
13.10. Companies with In-House Capabilities
13.11. Contract Manufacturers
13.12. Regulatory Landscape
14. COST PRICE ANALYSIS
14.1. Chapter Overview
14.2. Factors Contributing to the High Price of Cell / Gene Therapies
14.3. Pricing Models for CAR-T Cell Therapies
14.3.1. Based on Associated Costs
14.3.2. Based on Availability of Competing Products
14.3.3. Based on Target Patient Segment
14.3.4. Based on the Opinions of Industry Experts
14.4. Reimbursement-related Considerations for CAR-T Cell Therapies
14.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Overall CAR-T Cell Therapy Market, 2021-2030
15.4.1. CAR-T Cell Therapies Market: Distribution by Target Indication
15.4.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
15.4.3. CAR-T Cell Therapies Market: Distribution by Key Players
15.4.4. CAR-T Cell Therapies Market: Distribution by Geography
15.4.5. Product Wise Sales Forecast
15.4.5.1. KYMRIAH® (Novartis)
15.4.5.1.1. Target Patient Population
15.4.5.1.2. Sales Forecast (USD Million)
15.4.5.1.3. Net Present Value (USD Million)
15.4.5.1.4. Value Creation Analysis
15.4.5.2. YESCARTA® (Gilead Sciences)
15.4.5.2.1. Target Patient Population
15.4.5.2.2. Sales Forecast (USD Million)
15.4.5.2.3. Net Present Value (USD Million)
15.4.5.2.4. Value Creation Analysis
15.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
15.4.5.3.1. Target Patient Population
15.4.5.3.2. Sales Forecast (USD Million)
15.4.5.3.3. Net Present Value (USD Million)
15.4.5.3.4. Value Creation Analysis
15.4.5.4. BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics)
15.4.5.4.1. Target Patient Population
15.4.5.4.2. Sales Forecast (USD Million)
15.4.5.4.3. Net Present Value (USD Million)
15.4.5.4.4. Value Creation Analysis
15.4.5.5. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb)
15.4.5.5.1. Target Patient Population
15.4.5.5.2. Sales Forecast (USD Million)
15.4.5.5.3. Net Present Value (USD Million)
15.4.5.5.4. Value Creation Analysis
15.4.5.6. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
15.4.5.6.1. Target Patient Population
15.4.5.6.2. Sales Forecast (USD Million)
15.4.5.6.3. Net Present Value (USD Million)
15.4.5.6.4. Value Creation Analysis
15.4.5.7. MB-CART19.1 (Miltenyi Biotec)
15.4.5.7.1. Target Patient Population
15.4.5.7.2. Sales Forecast (USD Million)
15.4.5.7.3. Net Present Value (USD Million)
15.4.5.7.4. Value Creation Analysis
15.4.5.8. Descartes-11 (Cartesian Therapeutics)
15.4.5.8.1. Target Patient Population
15.4.5.8.2. Sales Forecast (USD Million)
15.4.5.8.3. Net Present Value (USD Million)
15.4.5.8.4. Value Creation Analysis
15.4.5.9. CD19 CAR-T (Sinobioway Cell Therapy)
15.4.5.9.1. Target Patient Population
15.4.5.9.2. Sales Forecast (USD Million)
15.4.5.9.3. Net Present Value (USD Million)
15.4.5.9.4. Value Creation Analysis
15.4.5.10. AUTO1 (Autolus)
15.4.5.10.1. Target Patient Population
15.4.5.10.2. Sales Forecast (USD Million)
15.4.5.10.3. Net Present Value (USD Million)
15.4.5.10.4. Value Creation Analysis
15.4.5.11. AUTO3 (Autolus)
15.4.5.11.1. Target Patient Population
15.4.5.11.2. Sales Forecast (USD Million)
15.4.5.11.3. Net Present Value (USD Million)
15.4.5.11.4. Value Creation Analysis
15.4.5.12. GPC3 CAR-T (Shanghai GeneChem)
15.4.5.12.1. Target Patient Population
15.4.5.12.2. Sales Forecast (USD Million)
15.4.5.12.3. Net Present Value (USD Million)
15.4.5.12.4. Value Creation Analysis
15.4.5.13. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
15.4.5.13.1. Target Patient Population
15.4.5.13.2. Sales Forecast (USD Million)
15.4.5.13.3. Net Present Value (USD Million)
15.4.5.13.4. Value Creation Analysis
15.4.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
15.4.5.14.1. Target Patient Population
15.4.5.14.2. Sales Forecast (USD Million)
15.4.5.14.3. Net Present Value (USD Million)
15.4.5.14.4. Value Creation Analysis
15.4.5.15. CD19 CAR-T (Shanghai Bioray Laboratory)
15.4.5.15.1. Target Patient Population
15.4.5.15.2. Sales Forecast (USD Million)
15.4.5.15.3. Net Present Value (USD Million)
15.4.5.15.4. Value Creation Analysis
15.4.5.16. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
15.4.5.16.1. Target Patient Population
15.4.5.16.2. Sales Forecast (USD Million)
15.4.5.16.3. Net Present Value (USD Million)
15.4.5.16.4. Value Creation Analysis
15.4.5.17. PCAR-019 (PersonGen BioTherapeutics)
15.4.5.17.1. Target Patient Population
15.4.5.17.2. Sales Forecast (USD Million)
15.4.5.17.3. Net Present Value (USD Million)
15.4.5.17.4. Value Creation Analysis
15.4.5.18. TBI-1501 (Takara Bio)
15.4.5.18.1. Target Patient Population
15.4.5.18.2. Sales Forecast (USD Million)
15.4.5.18.3. Net Present Value (USD Million)
15.4.5.18.4. Value Creation Analysis
15.4.5.19. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
15.4.5.19.1. Target Population
15.4.5.19.2. Sales Forecast (USD Million)
15.4.5.19.3. Net Present Value (USD Million)
15.4.5.19.4. Value Creation Analysis
15.4.5.20. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
15.4.5.20.1. Target Patient Population
15.4.5.20.2. Sales Forecast (USD Million)
15.4.5.20.3. Net Present Value (USD Million)
15.4.5.20.4. Value Creation Analysis
15.4.5.21. BinD19 (Shenzhen BinDeBio)
15.4.5.21.1. Target Patient Population
15.4.5.21.2. Sales Forecast (USD Million)
15.4.5.21.3. Net Present Value (USD Million)
15.4.5.21.4. Value Creation Analysis
15.4.5.22. CARCIK-CD19 (Formula Pharmaceuticals)
15.4.5.22.1. Target Patient Population
15.4.5.22.2. Sales Forecast (USD Million)
15.4.5.22.3. Net Present Value (USD Million)
15.4.5.22.4. Value Creation Analysis
15.4.5.23. EGFR CAR-T Cell Therapy (The Beijing Pregene Science and Technology)
15.4.5.23.1. Target Patient Population
15.4.5.23.2. Sales Forecast (USD Million)
15.4.5.23.3. Net Present Value (USD Million)
15.4.5.23.4. Value Creation Analysis
15.4.5.24. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
15.4.5.24.1. Target Patient Population
15.4.5.24.2. Sales Forecast (USD Million)
15.4.5.24.3. Net Present Value (USD Million)
15.4.5.24.4. Value Creation Analysis
15.4.5.25. PBCAR269A (Precision BioSciences and Servier)
15.4.5.25.1. Target Patient Population
15.4.5.25.2. Sales Forecast (USD Million)
15.4.5.25.3. Net Present Value (USD Million)
15.4.5.25.4. Value Creation Analysis
15.4.5.26. CD123 CAR-T cell Therapy (Chongqing Precision Biotechnology)
15.4.5.26.1. Target Patient Population
15.4.5.26.2. Sales Forecast (USD Million)
15.4.5.26.3. Net Present Value (USD Million)
15.4.5.26.4. Value Creation Analysis
15.4.5.27. BCMA CAR-T (Chongqing Precision Biotech)
15.4.5.27.1. Target Patient Population
15.4.5.27.2. Sales Forecast (USD Million)
15.4.5.27.3. Net Present Value (USD Million)
15.4.5.27.4. Value Creation Analysis
15.4.5.28. P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine)
15.4.5.28.1. Target Patient Population
15.4.5.28.2. Sales Forecast (USD Million)
15.4.5.28.3. Net Present Value (USD Million)
15.4.5.28.4. Value Creation Analysis
16. PROMOTIONAL ANALYSIS
16.1. Chapter Overview
16.2. Channels Used for Promotional Campaigns
16.3. Summary of Product Website Analysis
16.4. Summary of Patient Support Services and Informative Downloads
16.5. KYMRIAH®: Promotional Analysis
16.5.1. Drug Overview
16.5.2. Product Website Analysis
16.5.2.1. Messages for Healthcare Professionals
16.5.2.2. Messages for Patients
16.5.3. Patient Support Services and Informative Downloads
16.5.4. Other Promotional Activities
16.5.4.1. Presence in Conferences
16.6. YESCARTA®: Promotional Analysis
16.6.1. Drug Overview
16.6.2. Product Website Analysis
16.6.2.1. Messages for Healthcare Professionals
16.6.2.3. Messages for Patients
16.6.3. Patient Support Services and Informative Downloads
16.6.4. Other Promotional Activities
16.6.4.1. Presence in Conferences
17. COMPANY PROFILES
17.1. Chapter Overview
17.2. Autolus
17.3. bluebird bio
17.4. CARsgen Therapeutics
17.5. Celgene (A Bristol Myers Squibb Company)
17.6. Cellectis
17.7. Cellular Biomedicine Group
17.8. Innovative Cellular Therapeutics
17.9. Kite Pharma (A Gilead Sciences Company)
17.10. Kuur Therapeutics
17.11. Noile-Immune Biotech
17.12. Novartis
17.13. Shanghai Genechem
17.14. Sinobioway Cell Therapy
17.15. Takara Bio
17.16. Ziopharm Oncology
18. CONCLUDING REMARKS
18.1. Chapter Overview
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Cell Therapies
19.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
19.3. Celyad
19.3.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
19.4. Changhai Hospital
19.4.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
19.5. Glycostem Therapeutics
19.5.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
19.6. Gracell Biotechnologies
19.6.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
19.7. Kite Pharma
19.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
19.8. Theravectys
19.8.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
19.9. TxCell
19.9.1. Interview Transcript: Miguel Forte, Chief Operating Officer
19.10. University of Colorado
19.10.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
19.11. Waisman Biomanufacturing
19.11.1. Interview Transcript: Brian Dattilo, Manager of Business Development
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Historical Development of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3 Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5 Average Number of Likes, Re-tweets and Comments Related to CAR-T Cell Therapies
Figure 4.6 Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 5.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 5.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 5.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
Figure 5.5 CAR-T Cell Therapies: Distribution by Popular Target Antigens
Figure 5.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 5.7 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 5.8 CAR-T Cell Therapies: Distribution by Dose Frequency
Figure 5.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 5.10 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 5.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 6.2 CAR-T Cell Therapies: Popular Targets in Solid Tumor
Figure 6.3 CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4 CAR-T Cell Therapies: Prominent Key Opinion Leaders
Figure 6.5 CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.6 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.7 CAR-Construction: Analysis by Type of Vector
Figure 6.8 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 CAR-T Cell Therapy Clinical Trials: Distribution by Year of Registration and Geography (Pre-2016 and 2016-2019)
Figure 8.1 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancer: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Pancreatic Cancer: Global Epidemiological Distribution
Figure 9.9 Liver Cancer: Global Epidemiological Distribution
Figure 9.10 Breast Cancer: Global Epidemiological Distribution
Figure 9.11 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.12 Bladder Cancer: Global Epidemiological Distribution
Figure 9.13 Kidney Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing: Emerging Technology Platforms Used in CAR-T Cell Therapies
Figure 10.3 Competitiveness Analysis: Gene Editing Platforms
Figure 10.4 CAR-T Cell Therapies: Key Technologies to Enhance Features / Characteristics
Figure 10.5 Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.6 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Figure 11.2 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2013-2020
Figure 11.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Figure 11.5 Partnerships and Collaborations: Distribution by Individual Products
Figure 11.6 Partnerships and Collaborations: Most Active Industry Players
Figure 11.7 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 11.8 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Figure 11.10 Partnerships and Collaborations: Regional Distribution
Figure 11.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
Figure 12.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre 2013-2020 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Most Active Players: Distribution by Number of Funding Instances
Figure 12.6 Funding and Investment: Distribution by Types of Investor
Figure 12.7 Most Active Players: Distribution by Number of Instances
Figure 12.8 Funding and Investment Analysis: Distribution by Geography
Figure 12.9 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 13.1 Steps in Cell Therapy Manufacturing
Figure 13.2 Centralized Manufacturing: Process Model
Figure 13.3 Decentralized Manufacturing: Process Model
Figure 13.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 13.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 13.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 13.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 13.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 14.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 15.1 Overall CAR-T Cell Therapies Market, 2021-2030 (USD Billion)
Figure 15.2 CAR-T Cell Therapies Market: Distribution by Target Indication (USD Billion)
Figure 15.3 CAR-T Cell Therapies Market: Distribution by Target Antigen (USD Billion)
Figure 15.4 CAR-T Cell Therapies Market: Key Players (USD Billion)
Figure 15.5 CAR-T Cell Therapies Market: Distribution by Target Geography (USD Billion)
Figure 15.6 KYMRIAH® (Novartis): Current Status of Development
Figure 15.7 KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 15.8 YESCARTA® (Gilead Sciences): Current Status of Development
Figure 15.9 YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 15.10 TECARTUS® (Gilead Sciences): Current Status of Development
Figure 15.11 TECARTUS®: (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 15.12 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Current Status of Development
Figure 15.13 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.14 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Current Statusof Development
Figure 15.15 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, till 2030 (USD Million)
Figure 15.16 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Current Status of Development
Figure 15.17 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 15.18 MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 15.19 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 15.20 Descartes-11 (Cartesian Therapeutics): Current Status of Development
Figure 15.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.22 CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 15.23 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 15.24 AUTO1 (Autolus): Current Status of Development
Figure 15.25 AUTO1 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 15.26 AUTO3 (Autolus): Current Status of Development
Figure 15.27 AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 15.28 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 15.29 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 15.30 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 15.31 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030(USD Million)
Figure 15.32 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status ofDevelopment
Figure 15.33 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 15.34 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 15.35 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 15.36 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 15.37 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, Sales Forecast, till 2030 (USD Million)
Figure 15.38 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 15.39 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 15.40 TBI-1501 (Takara Bio): Current Status of Development
Figure 15.41 TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 15.42 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 15.43 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 15.45 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 15.46 BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 15.47 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 15.48 CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 15.49 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 15.50 EGFR CAR-T (The Beijing Pregene Science and Technology): Current Status of Development
Figure 15.51 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.52 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 15.53 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 15.54 PBCAR269A (Precision BioSciences and Servier): Current Status of Development
Figure 15.55 PBCAR269A (Precision BioSciences and Servier) Sales Forecast, till 2030 (USD Million)
Figure 15.56 CD123 CAR-T cells (Chongqing Precision Biotechnology): Current Status of Development
Figure 15.57 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 15.58 BCMA CAR-T (Chongqing Precision Biotech): Current Status of Development
Figure 15.59 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2030 (USD Million)
Figure 15.60 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Current Status of Development
Figure 15.61 P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine) Sales Forecast, till 2030 (USD Million)
Figure 16.1 Channels Used for Promotional Campaigns
Figure 16.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 16.3 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 16.4 Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 16.5 Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 16.6 Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 16.7 KYMRIAH®, Presence in Conferences
Figure 16.8 Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 16.9 Product Website Analysis: YESCARTA®, Messages for Patients
Figure 16.10 Product Website Analysis: YESCARTA®, Kite Konnect
Figure 16.11 Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 16.12 YESCARTA®, Presence in Conferences
Figure 18.1 Concluding Remarks: Overall Market Landscape
Figure 18.2 Concluding Remarks: Clinical Trial Analysis
Figure 18.3 Concluding Remarks: Partnerships & Collaborations and Funding and Investment Analysis
Figure 18.4 Concluding Remarks: Market Forecast
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.3 Key Characteristics of CAR-T Cells
Table 3.4 Comparison of First and Second-Generation CAR-Ts
Table 3.5 CD19 CAR-T Cells: Preclinical Results
Table 3.6 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 5.1 CAR-T Cell Therapies: Clinical Pipeline
Table 5.2 CAR-T Cell Therapies: Preclinical Pipeline
Table 6.1 CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2 CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3 BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4 BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5 Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6 Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7 GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8 GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9 CAR-T Cell Therapies: Principle Investigators
Table 6.10 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.1 CAR-T Cell Therapies: List of Clinical Trials
Table 7.2 Advanced Phase CAR-T Cell Therapies in China
Table 8.1 KYMRIAH®: Clinical Studies
Table 8.2 KYMRIAH®: Clinical Trial Endpoints (ALL)
Table 8.3 KYMRIAH®: Clinical Trial Endpoints (CLL / NHL / FL / MCL / CNSL)
Table 8.4 YESCARTA®: Clinical Studies
Table 8.5 YESCARTA®: Clinical Trial Endpoints
Table 8.6 TECARTUS® / Brexucabtagene Autoleucel: Clinical Studies
Table 8.7 TECARTUS® / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.8 JCAR Series: Molecules in Clinical Phase of Development
Table 8.9 JCAR: CAR-T Design
Table 8.10 JCAR014: Clinical Studies
Table 8.11 JCAR017: Clinical Studies
Table 8.12 JCAR018: Clinical Studies
Table 8.13 JCAR020: Clinical Studies
Table 8.14 JCAR023: Clinical Studies
Table 8.15 JCAR024: Clinical Studies
Table 8.16 JCARH125: Clinical Studies
Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19 JCAR: Dosage Regimen
Table 8.20 Idecabtagene Vicleucel / bb2121: Clinical Studies
Table 8.21 Idecabtagene Vicleucel / bb2121: Clinical Trial Endpoints
Table 8.22 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Studies
Table 8.23 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Trial Endpoints
Table 8.24 TBI-1501: Clinical Studies
Table 8.25 TBI-1501: Clinical Trial Endpoints
Table 8.26 TBI-1501: Dosage Regimen
Table 8.27 AUTO1: Clinical Studies
Table 8.28 AUTO3: Clinical Studies
Table 8.29 AUTO4: Clinical Studies
Table 8.30 Autolus’s Next Generation CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.32 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.33 Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.34 Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4 CAR-T Cell Therapies: Targets under Investigation for Leukemia
Table 9.5 CAR-T Cell Therapies: Targets under Investigation for Lymphoma
Table 9.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7 CAR-T Cell Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8 Melanoma: List of Marketed Targeted Therapeutics
Table 9.9 CAR-T Cell Therapies: Targets under Investigation for Melanoma
Table 9.10 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.11 CAR-T Cell Therapies: Targets under Investigation for Lung Cancer
Table 9.12 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 9.13 CAR-T Cell Therapies: Targets under Investigation for Pancreatic Cancer
Table 9.14 Liver Cancer: List of Marketed Targeted Therapeutics
Table 9.15 CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 9.16 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.17 CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 9.18 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.19 CAR-T Cell Therapies: Targets under Investigation for Ovarian Cancer
Table 9.20 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.21 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 10.1 Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Partnerships & Collaborations
Table 10.4 Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Partnerships & Collaborations
Table 10.10 Beam Therapeutics: Funding Instances
Table 10.11 Beam Therapeutics: Collaborations
Table 10.12 Gracell Biotechnologies: Funding Instances
Table 10.13 Cellectis: Funding Instances
Table 10.14 Cellectis: Partnerships & Collaborations
Table 10.15 bluebird bio: megaTAL Technology, Research Publications
Table 10.16 bluebird bio: Funding Instances
Table 10.17 bluebird bio: Partnerships & Collaborations
Table 10.18 Sangamo Therapeutics: Funding Instances
Table 10.19 Sangamo Therapeutics: Partnerships & Collaborations
Table 10.20 Cogent Biosciences: Funding Instances
Table 10.21 Cogent Biosciences: Partnerships & Collaborations
Table 10.22 Celyad Oncology: Funding Instances
Table 10.23 Celyad Oncology: Partnerships & Collaborations
Table 10.24 Glycostem: Funding Instances
Table 10.25 Glycostem: Partnerships & Collaborations
Table 10.26 Intrexon: Funding Instances
Table 10.27 Intrexon: Collaborations
Table 10.28 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.29 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.30 Bellicum Pharmaceuticals: Funding Instances
Table 10.31 Bellicum Pharmaceuticals: Collaborations
Table 10.32 Theravectys: Funding Instances
Table 10.33 Technologies For CAR-T Safety Enhancement
Table 10.34 Formula Pharmaceuticals: Collaborations
Table 11.1 CAR-T Cell Therapy Market: List of Partnerships and Collaborations, 2005-2020 (till October)
Table 12.1 CAR-T Cell Therapies: Funding and Investments, 2000-2020 (till October)
Table 12.2 CAR-T Cell Therapies Summary of Investments
Table 13.1 Assessment Strategies for Different Manufacturing Processes
Table 13.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 13.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 13.4 Cell Therapy Manufacturing: Contract Manufacturers
Table 14.1 Price of Marketed Gene / Cell Therapies
Table 14.2 Price of Marketed Targeted Drugs
Table 14.3 CAR-T Cell Therapies: Expert Opinions on Pricing
Table 14.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 15.1 CAR-T Cell Therapies: List of Forecasted Molecules
Table 15.2 KYMRIAH® (Novartis): Net Present Value (USD Million)
Table 15.3 KYMRIAH® (Novartis): Value Creation Analysis (USD Million)
Table 15.4 YESCARTA® (Gilead Sciences): Net Present Value (USD Million)
Table 15.5 YESCARTA® (Gilead Sciences): Value Creation Analysis (USD Million)
Table 15.6 TECARTUS®: (Gilead Sciences): Net Present Value (USD Million)
Table 15.7 TECARTUS®: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 15.8 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Net Present Value (USD Million)
Table 15.9 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Value Creation Analysis (USD Million)
Table 15.10 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Net Present Value (USD Million)
Table 15.11 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 15.12 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen): Net Present Value (USD Million)
Table 15.13 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech/ Janssen): Value Creation Analysis (USD Million)
Table 15.14 MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 15.15 MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 15.16 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 15.17 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 15.18 CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 15.19 CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 15.20 AUTO1 (Autolus): Net Present Value (USD Million)
Table 15.21 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 15.22 AUTO3 (Autolus): Net Present Value (USD Million)
Table 15.23 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 15.24 GPC3 CAR-T (Shanghai Genechem): Net Present Value (USD Million)
Table 15.25 GPC3 CAR-T (Shanghai Genechem): Value Creation Analysis (USD Million)
Table 15.26 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 15.27 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 15.28 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 15.29 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 15.30 CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 15.31 CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 15.32 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 15.33 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicineTechnology): Value Creation Analysis (USD Million)
Table 15.34 PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 15.35 PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USDMillion)
Table 15.36 TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 15.37 TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 15.38 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 15.39 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 15.40 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD
Table 15.41 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 15.42 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 15.43 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 15.44 CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 15.45 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 15.46 EGFR CAR-T (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 15.47 EGFR CAR-T (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 15.48 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 15.49 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 15.50 PBCAR269A (Precision BioSciences and Servier): Net Present Value (USD Million)
Table 15.51 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 15.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 15.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 15.54 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 15.55 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 15.56 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Net Present Value (USD Million)
Table 15.57 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Value Creation Analysis (USD Million)
Table 16.1 KYMRIAH®: Drug Overview
Table 16.2 YESCARTA®: Drug Overview
Table 17.1 Autolus: Company Profile
Table 17.2 bluebird bio: Company Profile
Table 17.3 CARsgen Therapeutics: Company Profile
Table 17.4 Celgene: Company Profile
Table 17.5 Cellectis: Company Profile
Table 17.6 Cellular Biomedicine Group: Company Profile
Table 17.7 Innovative Cellular Therapeutics: Company Profile
Table 17.8 Kite Pharma: Company Profile
Table 17.9 Kuur Therapeutics: Company Profile
Table 17.10 Noile-Immune Biotech: Company Profile
Table 17.11 Novartis: Company Profile
Table 17.12 Shanghai Genechem: Company Profile
Table 17.13 Sinobioway Cell Therapy: Company Profile
Table 17.14 Takara Bio: Company Profile
Table 17.15 Ziopharm Oncology: Company Profile
Table 20.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 20.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 20.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 20.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
Table 20.5 CAR-T Cell Therapies: Distribution by Popular Target Antigen
Table 20.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 20.7 CAR-T Cell Therapies: Distribution by Route of Administration
Table 20.8 CAR-T Cell Therapies: Distribution by Dose Frequency
Table 20.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 20.10 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 20.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Phase of Development
Table 20.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 20.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 20.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 20.15 CAR-T Cell Therapies: Popular Targets in Hematological Cancer
Table 20.16 CAR-T Cell Therapies: Popular Targets in Solid Tumor
Table 20.17 CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 20.18 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Table 20.19 CAR-Construction: Analysis by Type of Vector
Table 20.20 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 20.21 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 20.22 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 20.23 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Table 20.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.25 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Table 20.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 20.27 Partnerships and Collaborations: Distribution by Individual Products
Table 20.28 Partnerships and Collaborations: Most Active Industry Players
Table 20.29 Partnerships and Collaborations: Most Active Non-Industry Players
Table 20.30 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 20.31 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Table 20.32 Partnerships and Collaborations: Regional Distribution
Table 20.33 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.34 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
Table 20.35 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
Table 20.36 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 20.37 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 20.38 Most Active Players: Distribution by Number of Instances
Table 20.39 Funding and Investments: Distribution by Types of Investor
Table 20.40 Most Active Players: Distribution by Number of Instances
Table 20.41 Funding and Investment Analysis: Distribution by Geography
Table 20.42 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Table 20.43 Overall CAR-T Cell Therapies Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.44 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 20.45 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 20.46 CAR-T Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 20.47 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 20.48 KYMRIAH® (Novartis) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.49 YESCARTA® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.50 TECARTUS® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.51 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.52 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.53 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, Conservative,
Table 20.54 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.55 Descartes-11 (Cartesian Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.56 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.57 AUTO1 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.58 AUTO3 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.59 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.60 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.61 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.62 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.63 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.64 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.65 TBI-1501 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.66 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.67 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.68 BinD19 (Shenzhen BinDeBio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.69 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.70 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.71 Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.72 PBCAR269A (Precision BioSciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.73 CD123 CAR-T Cells (Chongqing Precision Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.74 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 20.75 P-BCMA-101 (Poseida Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Discounts available for multiple report purchases
sales@rootsanalysis.com